Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 1/2013

01-01-2013 | Correspondence

Artesunate- and Amodiaquine-Associated Extrapyramidal Reactions

Information Gained from an African-Based Risk Management Plan

Author: François Bompart

Published in: Drug Safety | Issue 1/2013

Login to get access

Excerpt

In an article recently published in Drug Safety [1], McEwen mentions that “… the Summary of Product Characteristics (SPC) for Artesunate Amodiaquine Winthrop® refers to somnolence, paraesthesias, headache, dizziness, convulsion and rare neuromyopathy. There is no mention of movement disorders, extrapyramidal disorders or their common pathognomonic symptoms, which is curious as the SPC purports to include additional types of events that have been attributed to amodiaquine in the published literature”. I think it may be helpful to provide further information on this. …
Literature
1.
McEwen J. Artesunate- and amodiaquine-associated extrapyramidal reactions: a series of 49 cases in VigiBase™. Drug Saf. 2012;35(8):667–75.PubMed
Metadata
Title
Artesunate- and Amodiaquine-Associated Extrapyramidal Reactions
Information Gained from an African-Based Risk Management Plan
Author
François Bompart
Publication date
01-01-2013
Publisher
Springer International Publishing AG
Published in
Drug Safety / Issue 1/2013
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-012-0010-x

Other articles of this Issue 1/2013

Drug Safety 1/2013 Go to the issue

Correspondence

Author’s Reply to Bompart: “Artesunate- and Amodiaquine-Associated Extrapyramidal Reactions: Information Gained from an African-Based Risk Management Plan”

Original Research Article

Adverse Drug Reactions to Gabapentin and Pregabalin

Original Research Article

Key Elements in Adverse Drug Interaction Safety Signals

Short Communication

A Reference Standard for Evaluation of Methods for Drug Safety Signal Detection Using Electronic Healthcare Record Databases

Short Communication

Pharmacovigilance in the Middle East

Original Research Article

Opportunities to Reduce Medication Regimen Complexity